Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: Impact of Ω-loop variations

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 10, 2016, Pages 2848-2855

  Lahiri, Sushmita D ^a,b   Bradford, Patricia A ^a   Nichols, Wright W ^a   Alm, Richard A ^a,b  

^a ASTRAZENECA   (United Kingdom)

^b Macrolide Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ASPARAGINE; AVIBACTAM; AZTREONAM; BACTERIAL ENZYME; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE GES; BETA LACTAMASE PER; CEFTAROLINE; CEFTAROLINE FOSAMIL; CEFTAZIDIME; CEFUROXIME; CLASS A BETA LACTAMASE; CLAVULANIC ACID; HYDROGEN; HYDROLASE; MEROPENEM; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; AZABICYCLO DERIVATIVE; BACTERIAL PROTEIN; BETA LACTAMASE INHIBITOR; BETA-LACTAMASE PER-1; PROTEIN BINDING;

AMINO ACID SUBSTITUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; CONSERVATION BIOLOGY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; ENZYME INHIBITION; ENZYME STRUCTURE; GENETIC VARIABILITY; HYDROGEN BOND; HYDROLYSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; BINDING SITE; CHEMISTRY; CLASSIFICATION; DRUG EFFECTS; ENZYMOLOGY; ESCHERICHIA COLI; GENETICS; HUMAN; KLEBSIELLA PNEUMONIAE; METABOLISM; MICROBIAL SENSITIVITY TEST; MOLECULAR MODEL; PROTEIN CONFORMATION;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTERIAL PROTEINS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; BINDING SITES; CEFTAZIDIME; ESCHERICHIA COLI; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; SEQUENCE ANALYSIS;

EID: 84994691830     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw248     Document Type: Article

References (47)

1. Boucher HW, Talbot GH, Benjamin DK Jr et al. 10×'20 progress-development of newdrugs active against Gram-negative bacilli: an update fromthe Infectious Diseases Society of America. Clin Infect Dis 2013; 56: 1685-94.
2. WHO. Antimicrobial Resistance: Global Report on Surveillance 2014. http://www.who.int/drugresistance/documents/surveillancereport/en/.
3. Bush K, Fisher JF. Epidemiological expansion, structural studies, and clinical challenges of new b-lactamases from Gram-negative bacteria. Annu Rev Microbiol 2011; 65: 455-78.
4. Holt KE, Wertheim H, Zadoks RN et al. Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in Klebsiella pneumoniae, an urgent threat to public health. Proc Natl Acad Sci USA 2015; 112: E3574-81.
5. Philippon A, Slama P, Deny P et al. A structureβased classification of class A b-lactamases, a broadly diverse family of enzymes. Clin Microbiol Rev 2016; 29: 29-57.
6. Knox JR. Extended-spectrum and inhibitor-resistant TEM-type b-lactamases: mutations, specificity, and three-dimensional structure. Antimicrob Agents Chemother 1995; 39: 2593-601.
7. Camargo JF, Simkins J, Beduschi T et al. Successful treatment of carbapenemase-producing pandrug-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother 2015; 59: 5903-8.
8. Ehmann DE, Jahic H, Ross PL et al. Kinetics of avibactam inhibition against class A, C, and D b-lactamases. J Biol Chem 2013; 288: 27960-71.
9. Ehmann DE, Jahic H, Ross PL et al. Avibactam is a covalent, reversible, nonβ-lactam b-lactamase inhibitor. Proc Natl Acad Sci USA 2012; 109: 11663-8.
10. Stachyra T, Pechereau MC, Bruneau JM et al. Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel nonβ-lactam b-lactamase inhibitor. Antimicrob Agents Chemother 2010; 54: 5132-8.
11. Lagace-Wiens P, Walkty A, Karlowsky JA. Ceftazidime-avibactam: an evidenceβased review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core Evid 2014; 9: 13-25.
12. Avycaz, Ceftazidime-Avibactam Prescribing Information. Cincinnati, OH, USA: Forest Pharmaceuticals, Inc., 2015.
13. Fernea A, Galleni M, Frere JM. Kinetics of the interaction between avibactam and the CHE-1 class C b-lactamase. J Antimicrob Chemother 2015; 70: 951-3.
14. Lahiri SD, Mangani S, Durand-Reville T et al. Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC b-lactamases. Antimicrob Agents Chemother 2013; 57: 2496-505.
15. Lahiri SD, Johnstone MR, Ross PL et al. Avibactam and class C b-lactamases: mechanism of inhibition, conservation of binding pocket and implications for resistance. Antimicrob Agents Chemother 2014; 58: 5704-13.
16. Lahiri SD, Mangani S, Jahic H et al. Molecular basis of selective inhibition and slow reversibility of avibactam against class D carbapenemases: a structure-guided study of OXA-24 and OXA-48. ACS Chem Biol 2015; 10: 591-600.
17. Papp-Wallace KM, Winkler ML, Taracila MA et al. Variants of b-lactamase KPC-2 that are resistant to inhibition by avibactam. Antimicrob Agents Chemother 2015; 59: 3710-7.
18. Keepers TR, Gomez M, Celeri C et al. Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against b-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2014; 58: 5297-305.
19. Lagace-Wiens PR, Tailor F, Simner P et al. Activity of NXL104 in combination with b-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum b-lactamases and class C b-lactamases. Antimicrob Agents Chemother 2011; 55: 2434-7.
20. Li H, Estabrook M, Jacoby GA et al. In vitro susceptibility of characterized b-lactamase-producing strains tested with avibactam combinations. Antimicrob Agents Chemother 2015; 59: 1789-93.
21. Livermore DM, Mushtaq S, WarnerMet al. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum b-lactamases and carbapenemases. J Antimicrob Chemother 2008; 62: 1053-6.
22. Yoshizumi A, Ishii Y, Aoki K et al. In vitro susceptibility of characterized b-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations. J Infect Chemother 2015; 21: 148-51.
23. Levasseur P, Girard AM, Miossec C et al. In vitro antibacterial activity of the ceftazidime-avibactam combination against Enterobacteriaceae, including strains with well-characterized b-lactamases. Antimicrob Agents Chemother 2015; 59: 1931-4.
24. Wang X, Zhang F, Zhao Cet al. In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrob Agents Chemother 2014; 58: 1774-8.
25. Flamm RK, Stone GG, Sader HS et al. Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value. J Chemother 2014; 26: 333-8.
26. Sader HS, Castanheira M, Flamm RK et al. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. Int J Antimicrob Agents 2015; 46: 53-9.
27. Walkty A, DeCorby M, Lagace-Wiens PR et al. In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob Agents Chemother 2011; 55: 2992-4.
28. Levasseur P, Girard AM, Claudon M et al. In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2012; 56: 1606-8.
29. Lahiri SD, Giacobbe RA, Johnstone MR et al. Activity of avibactam against Enterobacter cloacae producing an extended-spectrum class C b-lactamase enzyme. J Antimicrob Chemother 2014; 69: 2942-6.
30. Lahiri SD, Walkup GK, Whiteaker JD et al. Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC. J Antimicrob Chemother 2015; 70: 1650-8.
31. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard Tenth Edition: M07-A10. CLSI, Wayne, PA, USA, 2015.
32. Bartolome B, Jubete Y, Martinez E et al. Construction and properties of a family of pACYC184-derived cloning vectors compatible with pBR322 and its derivatives. Gene 1991; 102: 75-8.
33. Papp-Wallace KM, Bajaksouzian S, Abdelhamed AM et al. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactamagainst isogenic Escherichia coli strains expressing selected single b-lactamases. Diagn Microbiol Infect Dis 2015; 82: 65-9.
34. Tranier S, Bouthors AT, Maveyraud L et al. The high resolution crystal structure for class A b-lactamase PER-1 reveals the bases for its increase in breadth of activity. J Biol Chem 2000; 275: 28075-82.
35. Nordmann P, Ronco E, Naas T et al. Characterization of a novel extended-spectrum b-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1993; 37: 962-9.
36. Lahiri SD, Alm RA. Identification of novel VEB b-lactamase enzymes: Impact on avibactam inhibition. Antimicrob Agents Chemother 2016; 60: 3183-6.
37. Winkler ML, Papp-Wallace KM, Taracila MA et al. Avibactam and inhibitor-resistant SHV b-lactamases. Antimicrob Agents Chemother 2015; 59: 3700-9.
38. Helfand MS, Bethel CR, Hujer AM et al. Understanding resistance to b-lactams and b-lactamase inhibitors in the SHV b-lactamase: lessons from the mutagenesis of SER-130. J Biol Chem 2003; 278: 52724-9.
39. Wang X, Minasov G, Shoichet BK. The structural bases of antibiotic resistance in the clinically derived mutant b-lactamases TEM-30, TEM-32, and TEM-34. J Biol Chem 2002; 277: 32149-56.
40. Bradford PA. Automated thermal cycling is superior to traditional methods for nucleotide sequencing of bla(SHV) genes. Antimicrob Agents Chemother 1999; 43: 2960-3.
41. Veras DL, Alves LC, Brayner FA et al. Prevalence of the bla (SHV) gene in Klebsiella pneumoniae isolates obtained from hospital and community infections and from the microbiota of healthy individuals in Recife, Brazil. Curr Microbiol 2011; 62: 1610-6.
42. Jacob F, Joris B, Lepage S et al. Role of the conserved amino acids of the 'SDN' loop (Ser130, Asp131 and Asn132) in a class A b-lactamase studied by site-directed mutagenesis. Biochem J 1990; 271: 399-406.
43. Sougakoff W, L'Hermite G, Pernot L et al. Structure of the imipenemhydrolyzing class A b-lactamase SME-1 from Serratia marcescens. Acta Crystallogr D Biol Crystallogr 2002; 58: 267-74.
44. Bethel CR, Hujer AM, Hujer KM et al. Role of Asp104 in the SHV b-lactamase. Antimicrob Agents Chemother 2006; 50: 4124-31.
45. Shimizu-Ibuka A, Oishi M, Yamada S et al. Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum b-lactamase TOHO-1. Antimicrob Agents Chemother 2011; 55: 284-90.
46. Ruggiero M, Kerff F, Herman R et al. Crystal structure of the extendedspectrum b-lactamase PER-2 and insights into the role of specific residues in the interaction with b-lactams and b-lactamase inhibitors. Antimicrob Agents Chemother 2014; 58: 5994-6002.
47. Frase H, Toth M, Champion MM et al. Importance of position 170 in the inhibition of GES-type b-lactamases by clavulanic acid. Antimicrob Agents Chemother 2011; 55: 1556-62.